Robinson Bradshaw

Month: November 2009

Organizing the Company – Choice of Entity

In the first installments of the Bench to Market series, we discussed how to secure and protect intellectual property rights to technology that will be central to the venture. Once the entrepreneur is confident these rights are secure, it is time to form the legal entity that will carry on the business of developing the […]

Weekly Twitter Roundup

Each week there are a number of stories and developments that, for one reason or another, don’t find their way into a full-length posting on the Genomics Law Report. Here’s a recap of what I was Tweeting this week @genomicslawyer: Americans would participate in genetic research despite privacy concerns, according to @DNApolicy survey http://bit.ly/8lQ0we HT […]

From deCODE to Athleticode in DTC Genetic Testing

One week ago deCODE genetics declared bankruptcy and, yesterday, the Bankruptcy Court for the District of Delaware provided preliminary approval for deCODE’s liquidation plan, including the debtor-in-possession financing pledged by Saga Investments. deCODE’s struggles have been well chronicled, and there has been plenty of other discussion about whether direct-to-consumer (DTC) genetic testing is a commercially […]

Pre-implantation Genetic Screening: Socioeconomic Stratification and Equality of Opportunity

This commentary in the Genomics Law Report’s ongoing series What ELSI is New? is contributed by Austin Alexander, Siftgen, Inc. As the era of personal genomics comes of age, genomic information will play an increasingly important role not only in medical decisions but also in reproductive decisions. Already, preimplantation genetic screening (“PGS”, also referred to […]

Welcoming GINA into the Workplace

The most recent layer of federal antidiscrimination law took effect this past weekend – to the ADA, Title VII, FMLA and other federal and state laws, employers can add another: the Genetic Information Nondiscrimination Act. Title I of this new law (called GINA) took effect in May 2009, prohibiting health insurers and group plans from […]

Does a genomics that does not work for some mean a genomics that will not work for all?

This commentary in the Genomics Law Report’s ongoing series What ELSI is New? is contributed by Jenny Reardon, Department of Sociology and Center of Biomolecular Science and Engineering at UC Santa Cruz, and Stephanie M. Fullerton, Department of Bioethics and Humanities at the University of Washington. The future promise of personalized medicine rests precariously on […]

Weekly Twitter Roundup: Personalized Medicine Edition

Each week there are a number of stories and developments that, for one reason or another, don’t find their way into a full-length posting on the Genomics Law Report. In addition, this past week I attended the Partners Healthcare conference on Personalized Medicine, and provided live updates from a number of the sessions. So, this […]

deCODE Declares. Now What?

If you’re a regular reader of the Genomics Law Report – or the Wall Street Journal for that matter – by now you have probably heard the news: deCODE genetics, Inc. has filed for Chapter 11 Bankruptcy protection. Given deCODE’s recent financial struggles, this latest development is hardly a surprise. Indeed, two months ago, we […]

How should we deal with the arrival of very common prenatal testing for a broad set of genetic characteristics?

This commentary in the Genomics Law Report’s ongoing series What ELSI is New? is contributed by Hank Greely, Stanford University. Each year, about 60,000 pregnant women undergo prenatal genetic testing in the United States, out of more than 4.2 million live births. Within five years, new testing methods, made possible by the rise of cheap […]

23andMe’s New Game Plan: What it Means for the Company and for DTC Genetic Testing

Late Friday afternoon, direct-to-consumer (DTC) genetic testing company 23andMe announced a change in its game plan. Currently, 23andMe offers a single product – a $399 genotyping service that provides customers access to information about their genetic ancestry as well as genetic variants linked to certain other traits and diseases, including diabetes, Parkinson’s disease and certain […]